Thrivent Financial For Lutherans Denali Therapeutics Inc. Transaction History
Thrivent Financial For Lutherans
- $52.6 Billion
- Q3 2024
A detailed history of Thrivent Financial For Lutherans transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 138,862 shares of DNLI stock, worth $3.47 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
138,862
Previous 130,504
6.4%
Holding current value
$3.47 Million
Previous $3.03 Million
33.5%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding DNLI
# of Institutions
228Shares Held
120MCall Options Held
60.6KPut Options Held
48.4K-
Baillie Gifford & CO13.3MShares$334 Million0.3% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$329 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$279 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.7MShares$268 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.91MShares$198 Million0.05% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.35B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...